| Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. Co.'s lead clinical candidate, APVO436 is an ADAPTIR bispecific immunotherapeutic protein targeting CD123, a cell surface receptor highly expressed on several hematological malignancies and CD3, a component of the T-cell receptor. ALG.APV-527 is an investigational bispecific ADAPTIR candidate, partnered with Alligator Bioscience AB, featuring a mechanism of action designed to simultaneously target 4-1BB (CD137) and 5T4, a tumor antigen overexpressed in a number of different types of cancer. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate. We show 17 historical shares outstanding datapoints in our APVO shares outstanding history coverage, used to compute APVO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APVO market cap history over the course of time is important for investors
interested in comparing APVO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APVO versus a peer is one thing; comparing
APVO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APVO can fluctuate over the course of history.
With this page we aim to empower investors researching APVO by allowing them to research the APVO market cap history.